Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Stargardt Disease
DALLAS, Jan. 30, 2023 -- (Healthcare Sales & Marketing Network) -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the U.S. Food and Drug Administration ... Regenerative Medicine, Ophthalmology, FDA Nanoscope Therapeutics, Stargardt, optogenetic, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Marketing | Nanotechnology | Opthalmology | Pharmaceuticals | Vitamin A